DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

NASDAQ:DAWN • US23954D1090

10.6 USD
-0.05 (-0.47%)
At close: Feb 27, 2026
10.6 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall DAWN gets a fundamental rating of 4 out of 10. We evaluated DAWN against 521 industry peers in the Biotechnology industry. DAWN has a great financial health rating, but its profitability evaluates not so good. DAWN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • DAWN had negative earnings in the past year.
  • DAWN had a negative operating cash flow in the past year.
  • In the past 5 years DAWN always reported negative net income.
  • DAWN had a negative operating cash flow in each of the past 5 years.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • DAWN has a Return On Assets of -29.54%. This is in the better half of the industry: DAWN outperforms 66.99% of its industry peers.
  • The Return On Equity of DAWN (-33.66%) is better than 72.94% of its industry peers.
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • DAWN has a better Gross Margin (89.44%) than 91.75% of its industry peers.
  • DAWN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DAWN has more shares outstanding
  • The number of shares outstanding for DAWN has been increased compared to 5 years ago.
  • There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 8.89 indicates that DAWN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 8.89, DAWN belongs to the top of the industry, outperforming 80.23% of the companies in the same industry.
  • DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.89
ROIC/WACCN/A
WACC8.61%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • DAWN has a Current Ratio of 8.68. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 8.68, DAWN is doing good in the industry, outperforming 76.58% of the companies in the same industry.
  • A Quick Ratio of 8.55 indicates that DAWN has no problem at all paying its short term obligations.
  • DAWN has a Quick ratio of 8.55. This is in the better half of the industry: DAWN outperforms 76.39% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.55
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.13% over the past year.
EPS 1Y (TTM)42.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.97%

3.2 Future

  • The Earnings Per Share is expected to grow by 32.90% on average over the next years. This is a very strong growth
  • DAWN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.74% yearly.
EPS Next Y35.67%
EPS Next 2Y41.82%
EPS Next 3Y41.19%
EPS Next 5Y32.9%
Revenue Next Year49.98%
Revenue Next 2Y40.22%
Revenue Next 3Y41.77%
Revenue Next 5Y33.74%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DAWN's earnings are expected to grow with 41.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.82%
EPS Next 3Y41.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DAWN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (2/27/2026, 8:00:02 PM)

After market: 10.6 0 (0%)

10.6

-0.05 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-01
Inst Owners83.24%
Inst Owner Change-3.47%
Ins Owners2.36%
Ins Owner Change0.38%
Market Cap1.09B
Revenue(TTM)N/A
Net Income(TTM)-151.76M
Analysts82.5
Price Target23.59 (122.55%)
Short Float %12.24%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.36%
Min EPS beat(2)20.33%
Max EPS beat(2)36.38%
EPS beat(4)3
Avg EPS beat(4)1.46%
Min EPS beat(4)-73.33%
Max EPS beat(4)36.38%
EPS beat(8)5
Avg EPS beat(8)12.11%
EPS beat(12)9
Avg EPS beat(12)9.7%
EPS beat(16)11
Avg EPS beat(16)4.84%
Revenue beat(2)1
Avg Revenue beat(2)-1.85%
Min Revenue beat(2)-5.83%
Max Revenue beat(2)2.13%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-5.83%
Max Revenue beat(4)3.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.77%
PT rev (3m)-2.51%
EPS NQ rev (1m)8.26%
EPS NQ rev (3m)27.36%
EPS NY rev (1m)1.39%
EPS NY rev (3m)18.7%
Revenue NQ rev (1m)1.19%
Revenue NQ rev (3m)8.08%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)4.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.14
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS1.3
BVpS4.39
TBVpS4.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.44%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.44%
Cap/Sales 3.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.55
Altman-Z 8.89
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)635.28%
Cap/Depr(5y)471.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.75%
EPS Next Y35.67%
EPS Next 2Y41.82%
EPS Next 3Y41.19%
EPS Next 5Y32.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.97%
Revenue Next Year49.98%
Revenue Next 2Y40.22%
Revenue Next 3Y41.77%
Revenue Next 5Y33.74%
EBIT growth 1Y21.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.15%
EBIT Next 3Y23.01%
EBIT Next 5YN/A
FCF growth 1Y11.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.04%
OCF growth 3YN/A
OCF growth 5YN/A

DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ

Can you provide the ChartMill fundamental rating for DAY ONE BIOPHARMACEUTICALS I?

ChartMill assigns a fundamental rating of 4 / 10 to DAWN.


What is the valuation status for DAWN stock?

ChartMill assigns a valuation rating of 1 / 10 to DAY ONE BIOPHARMACEUTICALS I (DAWN). This can be considered as Overvalued.


What is the profitability of DAWN stock?

DAY ONE BIOPHARMACEUTICALS I (DAWN) has a profitability rating of 2 / 10.


How financially healthy is DAY ONE BIOPHARMACEUTICALS I?

The financial health rating of DAY ONE BIOPHARMACEUTICALS I (DAWN) is 8 / 10.